Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0001171843-17-002084
Filing Date
2017-04-12
Accepted
2017-04-12 12:10:40
Documents
5
Effectiveness Date
2017-04-12

Document Format Files

Seq Description Document Type Size
1 DEFINITIVE ADDITIONAL MATERIALS defa14a_041217.htm DEFA14A 12288
2 GRAPHIC proxy_01.jpg GRAPHIC 78269
3 GRAPHIC proxy_02.jpg GRAPHIC 122481
4 GRAPHIC proxy_03.jpg GRAPHIC 57958
5 GRAPHIC proxy_04.jpg GRAPHIC 28042
  Complete submission text file 0001171843-17-002084.txt   408594
Mailing Address 4505 EMPEROR BOULEVARD SUITE 200 DURHAM NC 27703
Business Address 4505 EMPEROR BOULEVARD SUITE 200 DURHAM NC 27703 919-859-1302
BIOCRYST PHARMACEUTICALS INC (Filer) CIK: 0000882796 (see all company filings)

EIN.: 621413174 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 000-23186 | Film No.: 17757423
SIC: 2836 Biological Products, (No Diagnostic Substances)